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The serine/threonine kinase, mTOR (mammalian Target of Rapamycin) has become a focus for cancer drug development.
Rapamycins are highly specific inhibitors of mTOR and potently suppress tumour cell growth by retarding cells in G1 phase or
potentially inducing apoptosis. Currently, both rapamycin and several analogues are being evaluated as anticancer agents in clinical
trials. Results indicate that many human cancers have intrinsic resistance and tumours initially sensitive to rapamycins become
refractory, demonstrating acquired resistance. Here, we consider mechanisms of resistance to inhibitors of mTOR.
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The mammalian target of rapamycin, mTOR is a serine/threonine
kinase evolutionarily conserved from yeast to human in the
catalytic domain. As the C-terminus of mTOR is highly homo-
logous to the catalytic domain of phosphatidylinositol 3 kinase
(PI3K), mTOR is considered a member of PI3K-related kinase
family (designated PIKK). The role of mTOR in cell growth,
metabolism, and cancer has been reviewed extensively (Bjornsti
and Houghton, 2004; Wullschleger et al, 2006). Signalling pathways
upstream and downstream of mTOR are presented in Figure 1.
Increasing evidence has implicated mTOR as a sensor that
integrates extracellular and intracellular events, coordinating cell
size (growth), proliferation, and survival. Mammalian target of
rapamycin may directly or indirectly regulate translation initiation
(through the mTOR-raptor [TORC1] complex), actin organisation
(through the mTOR-rictor [TORC2] complex), membrane traffick-
ing, protein degradation, ribosome biogenesis and tRNA synthesis,
as well as transcription. Mammalian target of rapamycin signalling
is negatively regulated by amino-acid deficiency and increased
AMP levels, suppressing cap-dependent protein synthesis. Thus,
mTOR in concert with tuberin and hamartin proteins that form the
tuberous sclerosis complex (TSC) and Rheb, appears to sense
nutrient and growth factor status, as well as energy charge, and
regulates progression from G1 to S phase.
CLINICAL DEVELOPMENT OF RAPAMYCIN
ANALOGUES
A number of clinical trials with the rapalogues (CCI-779, RAD001,
and AP23573; Figure 1) have now been completed. The phase I trial
evaluating the safety of CCI-779 was examined for both daily and
weekly i.v. treatment in patients with a number of different types
of tumours (Dancey, 2002). Objective responses (non-small-cell
carcinoma, neuroendocrine, and breast carcinomas), and minor
responses or stable disease (cervical carcinoma, uterine carcinoma,
renal cell carcinoma, and soft tissue sarcoma) were observed.
Phase II trials for renal cell carcinoma yielded an objective
response rate of 5–7%, a minor response rate of 26–29%, and
stable disease in approximately 40% of the patients (Atkins et al,
2004). Treatment is associated with an increase in survival time of
approximately 4 months. For Mantle cell lymphoma, an overall
response rate of 38% (3% complete response and 35% partial
response), with a median time to progression of 6.9 months in
responders vs 6.5 months for all patients treated (Witzig et al,
2005). CCI-779 appears to have significant activity in endometrial
cancer, irrespective of PTEN (phosphatase and tensin homologue
deleted on chromosome ten) status, yielding objective responses in
25% of patients, and causing disease stabilisation in over half of
the patients on study. Median progression-free survival was 8
months. For AP23573, phase II results suggest significant activity
in approximately 30% of patients with previously treated subtypes
of sarcoma. Thus, in these studies there is clear evidence of
acquired resistance where tumour growth is initially arrested but
where relapse occurs on treatment with rapamycin analogues. In
contrast, the majority of patients with advanced breast cancer
(overall response rate of 9.2%) appear to exhibit intrinsic
resistance to this class of agent (Chang et al, 2005).
MECHANISM OF ACTION OF RAPAMYCINS
Rapamycin and its analogues in clinical development are highly
specific inhibitors of mTOR, and differ only slightly in chemical
structure (Figure 1) that results in improved chemical stability and
pharmaceutical properties. Rapamycins bind a Mr 12000 cytosolic
immunophilin termed FK-binding protein (FKBP-12). The FKBP–
rapamycin complex binds to the FK–rapamycin binding (FRB)
domain of mTOR, resulting in inhibition of the function of mTOR
in the TORC1 complex. Whether rapamycin or FKBP–rapamycin
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controversial, rather FKBP–rapamycin complex may disrupt
higher order mTOR–protein complexes, perhaps displacing
substrates from the catalytic domain (Bjornsti and Houghton,
2004). As each of the rapalogues in clinical development has an
essentially identical mechanism of action, it is probable that
resistance mechanisms will be similar.
RAPAMYCIN-SENSITIVE SIGNALLING PATHWAYS
MEDIATED BY mTOR
4E-BP1 and S6K1 are the best characterised downstream effector
molecules of mTOR. 4E-BP1 functions as a suppressor of
eukaryotic initiation factor 4E (eIF4E), the mRNA cap-binding
protein. In response to mitogens, six sites of 4E-BP1 can be
phosphorylated (Shah et al, 2000). In the presence of rapamycin,
4E-BP1 becomes hypo-phosphorylated and associates with eIF4E,
preventing binding of eIF4E to the scaffold protein eIF4G and
formation of the eIF4F pre-initiation complex required for cap-
dependent translation of mRNA. As a result, rapamycin may
downregulate mTOR-controlled synthesis of essential proteins
involved in cell cycle progression, such as cyclin D1 and
ornithinine decarboxylase, and survival (hypoxia inducible factor
1a, and c-MYC).
S6K1 and S6K2, downstream of mTOR, are both inhibited by
rapamycin (Jefferies et al, 1997). Similar to 4E-BP1, activation of
S6K1 requires hierarchical phosphorylation. In vitro, mTOR
phosphorylates only Thr389 in the regulatory domain. A recent
model proposed by the Blenis laboratory suggests that S6K1 is
phosphorylated in the pre-initiation complex by mTOR leading to
dissociation and full activation of S6K1 by PDK1. Activated S6K1
phosphorylates eIF4B, which then binds in the pre-initiation
complex (Holz et al, 2005).
REGULATION OF SENSITIVITY TO mTOR
INHIBITION BY SIGNALLING PATHWAYS
Phosphatase and tensin homologue deleted on chromosome ten
(PTEN) is a dual-specificity protein phosphatase, and functions as
a major negative regulator of the PI3-kinase/Akt signalling
pathway. Loss of PTEN occurs frequently in human tumours
(Vivanco and Sawyers, 2002), resulting in hyperphosphorylation
or activation of Akt. Activated Akt positively regulates mTOR-
dependent pathways through inhibition of the TSC complex, and
forms the basis for rapamycin hypersensitivity of PTEN-deficient
or -mutant cells. Either loss of PTEN or activation of Akt resulted
in an increased sensitivity to the rapalogue CCI-779 in a panel of
brain, prostate, breast cancer cell lines, and human tumours
implanted in athymic nude mice (Yu et al, 2001). Most CCI-779-
resistant tumour cells had a low or moderate level of activated Akt,
although there are exceptions where loss of PTEN is not associated
with hypersensitivity to CCI-779. In contrast to CCI-779 resistant
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Figure 1 Chemical structure of rapamycin and its analogues currently in clinical trials as anticancer chemotherapeutic agents. Bars indicate the chemical
modifications to rapamycin.
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lacked expression of the tumour suppressor PTEN, and/or
overexpressed the Her-2 oncogene. One proposed mechanism by
which low Akt activity induces rapamycin resistance is through
allowing continued cap-independent protein synthesis of cyclin D1
and c-MYC proteins. The cyclin D1 mRNA 50 untranslated region
contains an internal ribosome entry site (IRES) and both this IRES
and the c-MYC IRES are negatively regulated by Akt activity, and
the function of both IRES’s is enhanced following exposure to
rapamycin. Hence, continued IRES-mediated translation initiation
may permit cell cycle progression upon mTOR inactivation in cells
in which Akt kinase activity is relatively low (Shi et al, 2005). Thus,
one biomarker for intrinsic rapamycin resistance may be low levels
of activation of Akt. On the other hand, rapamycin sensitivity of
breast cancer lines correlated inversely with phospholipase D
(PLD) activity. Elevating PLD activity led to rapamycin resistance,
and inhibition of PLD activity increased rapamycin sensitivity.
This is consistent with the notion that PLD-generated phosphatidic
acid competes for rapamycin–FKBP binding to mTOR. In yeast,
activation of the RAS/cAMP signalling pathway also confers
pronounced resistance to rapamycin (Schmelzle et al, 2004); how-
ever, this association has not been reported for mammalian cells.
MUTATIONS IN FKBP12 AND mTOR
Although direct inhibitors of mTOR kinase activity are being
developed, most data on mechanisms of resistance apply to
rapamycins. Rapamycin first binds FKBP-12 in mammalian cells.
Either specific mutations in FKBP12 that prevent the formation of
FKBP–rapamycin complex, or mutations in the FRB domain of
mTOR that decrease the affinity of binding of the FKBP–
rapamycin complex would cause rapamycin resistance. Such
mutations were first found in the yeast Saccharomyces cerevisiae,
where deletion of the RBP1 gene (a homologue of mammalian
FKBP-12) resulted in recessive resistance to rapamycin, and
expression of RBP1 restored rapamycin sensitivity. In mouse mast
cells, mutations in FKBP-12 that substantially reduced binding
affinity of FKBP-12 for rapamycin, rendered rapamycin resistance
(Fruman et al, 1995). Resistance to rapamycin selected after
mutagenesis is related to a dominant phenotype consistent with
mutation in the FRB domain of mTOR (Dumont et al, 1995).
Expression of an FRB-mutant mTOR (Ser2035-Ile), having
reduced affinity for binding the FKBP–rapamycin complex,
confers high-level resistance (Dumont et al, 1995), Figure 2A.
DYSREGULATION OF eIF4E
4E-BP1, the suppressor of eIF4E, has been widely recognised as the
other primary downstream effector of mTOR. Acquired resistance
to rapamycin was associated with decreased levels (B10-fold) of
4E-BP1, the suppressor of eIF4E (Dilling et al, 2002) owing to
decreased translation of 4E-BP1. In cells that reverted to
rapamycin sensitivity, total levels of 4E-BP1 became similar to
those in parental cells, and 4E-BP1 bound to eIF4E had similar
response to serum starvation and IGF-I stimulation as found in
parental cells. These data suggest that decrease of 4E-BP1
expression results in dysregulation of eIF4E, conferring rapamycin
resistance.
These results indicate that the rapamycin-regulated eIF4E
pathway is crucial in inducing growth arrest, and dysregulation
of eIF4E may facilitate the malignant phenotype. This is supported
by clinical observations that dysregulation of the eIF4E pathway is
associated with tumour progression (Nathan et al, 1997). In
addition to decreased 4E-BP1 expression, increased eIF4E expres-
sion in mice is tumorigenic and increases the rate of tumour
progression. When 4E-BP1 is overexpressed in highly resistant
HCT8 cells (IC50410000ngml
 1), they become sensitive (IC50
o10ngml
 1) to rapamycin (Dilling et al, 2002). Potentially, the
ratio of 4E-BP to eIF4E may determine whether inhibition of
mTOR elicits a biologically significant tumour response
(Figure 2A).
DEFECTIVE REGULATION OF THE
RETINOBLASTOMA (RB) PROTEIN CHECKPOINT
In malignant cells, the RB checkpoint can be bypassed by loss of
RB protein or function, loss of p27
Kip1, and overexpression of
cyclin E or other cyclins. The role of p27
Kip1 in modulating
rapamycin sensitivity (Luo et al, 1996) implies that mTOR has a
role in controlling the phosphorylation state of RB, however, this
may be cell-context specific. Rapamycin prevents mitogen-
stimulated downregulation of the cdk inhibitor p27
Kip1 and
suggests that p27
Kip1 is involved in the antiproliferative activity
of rapamycin. Prolonged culture of sensitive cells in the presence
of drug resulted in rapamycin-resistant clones that exhibited low
p27
Kip1 protein, no decrease in mRNA level but a high rate of
ubiquitin-independent degradation. p27
Kip1 in resistant cells could
not be regulated either in response to serum or rapamycin, and as
a result, RB phosphorylation was not blocked. However, only
partial resistance to antiproliferative activity of rapamycin was
found in p27
 /  mouse embryo fibroblasts (MEFs) and p27
 / 
splenic T lymphocytes, indicating that there exist p27-dependent
and -independent pathways that determine rapamycin sensitivity
(Figure 1B). Rapamycin also inhibits insulin-induced RB phos-
phorylation in 3T3-L1 adipocytes but not in rapamycin-sensitive
NIH3T3 fibroblasts where rapamycin does not alter the phosphor-
ylation status of RB or two RB-related proteins p107 and p130.
Similarly, in Ba/F3 p210 cells expressing BCR/ABL, rapamycin
arrested growth, but failed to alter the hyperphosphorylation of RB
protein (Gesbert et al, 2000). RB-null MEFs, however, are highly
resistant to rapamycin (IC50 410mgml
 1) relative to wild-type
cells (IC50B1ngml
 1) (unpublished data) (Figure 2B).
FKBP12
mTOR 4E-BP eIF4E Cyclin D1
Cyclin D1
CDK4/6 p27 RB
Cell cycle
progression
Cell cycle
progression
A
B
Figure 2 (A) Predicted mechanisms of resistance to rapamycin
analogues. Rapamaycin or its derivatives (red balls) can be eliminated
from cells by ABC transporters such as P-glycoprotein. Mutations of FKBP
or mTOR (yellow stars) confer resistance. Acquired resistance to
rapamycin has been associated with decreased stoichiometry between
4E-BP and eIF4E, either through decreased translation of 4E-BP or
overexpression of eIF4E. (B) Inhibition of mTOR leads to decreased
translation of cyclin D1 mRNA, and reduced levels of cyclin D1. In many
cells, there is a concomitant stabilisation of the cyclin-dependent kinase
inhibitor p27
Kip1, and inhibition of CDK-cyclin activity, and decreased
phosphorylation of RB. Cells deficient in p27
Kip1 are partially resistant,
whereas RB-null cells are completely resistant to inhibition of proliferation
by rapamycin.
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p53 is a tumour suppressor and transcription factor that has been
found to be mutated in B50% of human cancers and p53 status
may also determine the cellular response to rapamycin (Huang
et al, 2003). When cultured under autocrine conditions (serum-
free) p53
þ/þ MEFs exposed to rapamycin accumulate in G1 phase
and maintain viability, whereas p53-mutant cells accumulate in G1
phase and undergo apoptosis. In p53-defective cells, inhibition of
mTOR leads to a rapid and maintained induction of a stress
response characterised by increased phospho-c-Jun, whereas in
cells with functional p53 this stress response is suppressed (Huang
et al, 2003). Mechanistically, inhibition of mTOR leads to
decreased activity of protein phosphatase 5 (PP5) and activation
of apoptosis signal regulating kinase 1. Rapamycin-induced
apoptosis can be inhibited by expression of functional p53, by
overexpression of PP5, decreased expression of 4E-BP1, or
overexpression of Bcl2.
MUTATIONS OF PP2A-RELATED PROTEIN
PHOSPHATASES
Several serine/threonine protein phosphatases have been identified
as the components of mTOR signalling pathway in mammalian
cells (Dennis et al, 1999). Rapamycin resistance caused by
mutations of PP2A-related phosphatases was first found in yeast.
Studies in mammalian cells also indicate that association of a4 (the
homologue of yeastTap42) with PP2A, PP4, and PP6 is related to
rapamycin sensitivity (Murata et al, 1997). For example, in
rapamycin-sensitive Jurkat cells, rapamycin dissociated a4 from
PP2Ac, and transfection of mouse a4 into Jurkat cells conferred
rapamycin resistance. In rapamycin-resistant Raji cells, rapamycin
did not affect association of a4 with PP2Ac. However, other studies
have not demonstrated rapamycin-induced dissociation of a4 from
PP2A or PP6. Thus, at this time the significance of a4 to rapamycin
resistance is controversial.
MUTATIONS OF ATM
ATM (ataxia telangiectasia, mutated) cells have been reported to
be rapamycin resistant. In contrast, early passage murine embryo
fibroblasts derived from ATM
 /  mice are not resistant to
rapamycin (Germain and Houghton, unpublished data) distin-
guishing the null phenotype from the ATM mutant cells. As ATM
cells have genetic instability, it is possible that resistance to
rapamycin is a consequence of additional mutations and not
related directly to defects in ATM signalling.
MUTATIONS OF 14-3-3
In yeast, the two homologues of the mammalian 14-3-3 proteins
act as multicopy suppressors of the growth-inhibitory phenotype
caused by rapamycin (Bertram et al, 1998). Overexpression of
either BMH1 or BMH2, or three human 14-3-3 isoforms (b, t, and
Z) in yeast conferred rapamycin resistance, whereas disruption
sensitised to rapamycin. The mechanism by which 14-3-3 proteins
cause rapamycin resistance is not known; however, potentially 14-
3-3 proteins may play a role in determining rapamycin sensitivity
in mammalian cells.
PREVENTION OF APOPTOSIS BY GROWTH FACTORS
AND CYTOKINES
Substantial data support a role for mTOR signalling through the
eIF4E pathway in promoting cell survival, although exogenous
factors may modulate the apoptotic response to mTOR inhibition.
IGF-I or insulin protect from rapamycin-induced apoptosis
(Kurmasheva and Houghton, 2006) by activating Akt-dependent
and -independent pathways resulting in phosphorylation and
inactivation of the proapoptotic protein Bad, thus promoting the
activity of Bcl2. Overexpression of Bcl2 also confers resistance to
rapamycin-induced cell killing.
Anecdotally, in many cell lines and patient tumour biopsies
(O’Reilly et al, 2006), inhibition of mTOR activates Akt and
inhibits downstream substrates (FoxO transcription factors, Bad,
and GSK3a/b). Increased phospho-Akt was correlated with
increased levels of IRS-1 but not IRS-2. IRS-1 is phosphorylated
by S6K1 at Ser312 resulting in its dissociation from the IGF-1
receptor, and proteasome-mediated degradation (Shi et al, 2005).
Inhibition of mTOR inactivates S6K1 and stabilises IRS-1
associated with receptors, thus alleviating this negative regulation.
Inhibition of IGF-1R abrogated rapamycin-induced phospho-Akt
induction and substrate phosphorylation, and combination of
rapamycin with an inhibitor of IGF-1R had additive effects on
proliferation irrespective of PTEN status and increased apoptosis
in a PTEN mutant cancer cell line (O’Reilly et al, 2006). Thus,
either exogenous IGF-1 or derepression of IRS-1 in the presence of
rapamycin may induce resistance to growth inhibition or
apoptosis induced by mTOR inhibition (see Easton et al, 2006).
Similarly IL-3 induces expression of Pim-2 and confers resistance
to rapamycin, probably through the dual action of phosphorylat-
ing 4E-BP1 and Bad. Pim kinases are components of the
transcriptional response to cytokines or antigen receptor ligation,
and overexpression of Pim-1 or Pim-2 can maintain 4E-BP1
phosphorylation (Ser65) in the presence of rapamycin, conferring
resistance. Consistent with the role of Pim kinases modulating the
activity of mTOR inhibitors, Pim-2
 /  or Pim-1
 / Pim-2
 /  cells
are hypersensitive to rapamycin (Fox et al, 2005).
INHIBITION OF mTOR IN TORC2 COMPLEXES
Mammalian target of rapamycin complexed with rictor (TORC2) is
thought to be insensitive to rapamycin, and to play a role in
regulating the actin cytoskeleton (Wullschleger et al, 2006). The
TORC2 complex phosphorylates Akt at Ser473, and consequently
may regulate both survival through Akt, and also TORC1 (mTOR-
raptor) activity. Prolonged inactivation of TORC1 by rapamycin
potentially leads to a shift of mTOR from the TORC2 complex to
being rapamycin-bound, and lead to decreased Akt activation,
activation of GSK-3b (which regulates cyclin D1 proteolysis, and
enhances rapamycin-mediated growth inhibition), and apoptosis.
Thus, for direct inhibitors of mTOR kinase, the potential for
upregulation of Akt via the IRS-1 pathway and protection from cell
death seems less likely. The TORC2 complex will also be targeted
by direct mTOR kinase inhibitors that bind into the ATP pocket of
the catalytic domain. By analogy to acquired resistance mechan-
isms to imatinib or gefitinib that frequently are caused by
mutations in ATP-binding site for BCR-ABL and ERBB1,
respectively, it is probable that ATP-mimetic mTOR inhibitors
will select for binding site mutants.
ABC-TRANSPORTERS
The ability of cyclosporin A, FK506, and rapamycin to overcome
P-glycoprotein-mediated multidrug resistance has been demon-
strated (Arceci et al, 1992). The multidrug resistance-reversing
activity increased in the order rapamycin oFK506 o cyclosporin
A, irrespective of whether the resistant cells overexpressed hamster
or human P-glycoprotein. The interaction of the three macrolides
with P-glycoprotein was characterised by their ability bind with
high affinity to P-glycoprotein, and to competitively inhibit the
photoaffinity labelling of plasma membranes of drug-resistant cells
by iodomycin. Although an inhibitor of P-glycoprotein activity
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basal rate, it did not completely inhibit the activity. Hence,
rapamycin can be classified as a substrate for transport by P-
glycoprotein (Kerr et al, 2001), as a consequence tumours
overexpressing P-glycoprotein (MDR1) may be resistant to
rapamycins (Figure 1A).
ANGIOGENESIS-ASSOCIATED RESISTANCE
MECHANISMS
Guba et al (2002) first reported the anecdotal result where cells
were resistant to rapamycin in vitro, but tumours from the same
cells in mice were growth inhibited by rapamycin treatment. They
concluded that the antitumor activity of rapamycin was due to its
antiangiogenic activity as rapamycin decreased production of
vascular endothelial growth factor (VEGF) and markedly inhibited
response of vascular endothelial cells to stimulation by VEGF.
Similar results have been obtained with human cancer cell lines
that are intrinsically resistant to rapamycin analogues in vitro, but
where in vivo growth of tumour xenografts is inhibited
significantly. The mTOR pathway controls cap-dependent transla-
tion, and hence potentially levels of hypoxia inducible factor 1a
(HIF-1a), cellular proliferation, and migration. Thus, inhibition of
mTOR may have direct effects on cancer cell proliferation and
survival, indirect effects via inhibition of HIF-1a, thus reducing
tumour-elicited VEGF, direct effects on vascular endothelial cells,
or vascular smooth muscle cells (Humar et al, 2002; Majumder
et al, 2004). For example, induction of HIF-1a and VEGF by the
CML-associated oncogene, BCR-ABL, is mTOR-dependent (Mayer-
hofer et al, 2002), and in vitro, rapamycin inhibited VEGF
production in primary cultures from BCR-ABL transformed,
imatinib resistant, CML (Mayerhofer et al, 2005). The role for
mTOR in VEGF production is supported by regulation of HIF-1a
by mTOR signalling and increased VEGF in cells deficient in the
TSC that negatively regulates mTOR via Rheb (Hudson et al, 2002).
However, other studies support a role mainly for PI3K and to a
lesser extent mTOR being required for insulin-induced HIF-1a
expression (Treins et al, 2002). Our studies indicate that
rapamycin treatment has little effect on hypoxia-driven VEGF
production in most rhabdomyosarcoma or neuroblastoma cell
lines (Kurmasheva et al, submitted). Thus, in these cells it is
unlikely that rapamycin would block tumour-derived VEGF,
although it may directly block the response of vascular endothelial
or other stromal cells in tumour tissue. Potentially, in vivo
resistance to mTOR inhibition could be elicited by secretion of
angiogenic factors that signal to stromal cells via mTOR-
independent pathways to increase proliferation or motility of
vascular cells.
CONCLUSIONS
The mechanisms for resistance to rapamycin analogues are likely
to be complex. In part, it remains unclear exactly why inhibition of
mTOR signalling results in growth inhibition, as inhibition of
mTOR signalling appears similar in rapamycin-sensitive or -
resistant cell lines. It is also probable that resistance mechanisms
will be similar for the rapalogues currently in clinical development.
The mechanism(s) for resistance to catalytic kinase inhibitors,
however may more likely relate to mTOR mutations within the
ATP binding site as identified for imatinib and gefitinib. Although
preclinical models can suggest potential mechanisms for
resistance to rapamycins, it is of critical importance to characterise
tumour biopsy tissue at initiation of treatment and at subsequent
relapse in order to ascertain which mechanisms apply to clinical
cancer.
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